Premium Alternative Insight and Premium Journalism
While others, including Tiger Global, Lone Pine, Maverick, Viking, Valiant, D1, and Coatue, reported mixed performance in the first half of the year.
The Latest
Several life sciences and biopharma hedge funds are on pace to do more deals than they did in each of the three previous years.
David Einhorn’s hedge fund greatly lagged the market last month as well as in the first half of the year.
According to SEI Novus’s list of the firms’ most widely held stocks, only nine of 20 lost money in the past three months.
The quant pioneer is capitalizing on banks’ need to better manage risk, optimize balance sheets, and improve long-term profitability.
In the second quarter, most firms previously known for their hedge funds’ activity in the private markets continued to sit out.
One of the largest hedge fund firms is gearing up for a foreign company’s listing in the U.S. this week.
Robert Citrone’s macro fund is one of the strategy leaders this year.
Sponsored
Increased complexity brings greater flexibility – and opportunity
More in Premium
Sponsored